EP0730660A4 - Proteines chimeres contenant des variantes de la protease nexine-1 - Google Patents

Proteines chimeres contenant des variantes de la protease nexine-1

Info

Publication number
EP0730660A4
EP0730660A4 EP94931834A EP94931834A EP0730660A4 EP 0730660 A4 EP0730660 A4 EP 0730660A4 EP 94931834 A EP94931834 A EP 94931834A EP 94931834 A EP94931834 A EP 94931834A EP 0730660 A4 EP0730660 A4 EP 0730660A4
Authority
EP
European Patent Office
Prior art keywords
variants
chimeric proteins
proteins including
protease nexin
including protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94931834A
Other languages
German (de)
English (en)
Other versions
EP0730660A1 (fr
Inventor
Randy W Scott
Scott M Braxton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals Inc filed Critical Incyte Pharmaceuticals Inc
Publication of EP0730660A1 publication Critical patent/EP0730660A1/fr
Publication of EP0730660A4 publication Critical patent/EP0730660A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP94931834A 1993-10-29 1994-10-28 Proteines chimeres contenant des variantes de la protease nexine-1 Withdrawn EP0730660A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US144758 1980-04-28
US14475893A 1993-10-29 1993-10-29
PCT/US1994/011624 WO1995011987A1 (fr) 1993-10-29 1994-10-28 Proteines chimeres contenant des variantes de la protease nexine-1

Publications (2)

Publication Number Publication Date
EP0730660A1 EP0730660A1 (fr) 1996-09-11
EP0730660A4 true EP0730660A4 (fr) 1998-02-25

Family

ID=22510003

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94931834A Withdrawn EP0730660A4 (fr) 1993-10-29 1994-10-28 Proteines chimeres contenant des variantes de la protease nexine-1

Country Status (4)

Country Link
EP (1) EP0730660A4 (fr)
JP (1) JPH09504174A (fr)
AU (1) AU685187B2 (fr)
WO (1) WO1995011987A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
NZ336839A (en) 1997-02-21 2001-08-31 Genentech Inc Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
AU7553698A (en) * 1997-05-12 1998-12-08 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Method and construct for inhibition of cell migration
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7005504B2 (en) 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
EP2158923B1 (fr) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Conjugués peg-urate oxydase et utilisation associée
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
JP2002534119A (ja) * 1999-01-14 2002-10-15 ボルダー バイオテクノロジー， インコーポレイテッド 自由システイン残基を有するタンパク質の生産方法
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
ATE298346T1 (de) 1999-12-06 2005-07-15 Chu Sainte Justine Verbindungen zur behandlung von abnormaler glomerularer filtration, patent ductus arteriosus und osteoporosis
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US20020042388A1 (en) 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
WO2002055532A2 (fr) * 2001-01-11 2002-07-18 Maxygen Aps Molecules d'hormone de croissance ameliorees
WO2003029420A2 (fr) * 2001-10-02 2003-04-10 Genentech, Inc. Variants de ligands apo-2 et leurs utilisations
US6908963B2 (en) * 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1490402A4 (fr) * 2002-03-20 2007-05-02 Biopolymed Inc Preparation d'un g-csf stoechiometriquement conjugue a des polymeres biocompatibles au niveau d'un residu de cysteine
EP2500032A1 (fr) * 2002-06-24 2012-09-19 Genentech, Inc. Variantes du ligand/Trail APO-2 et leurs utilisations
JP4490290B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US7790835B2 (en) 2003-12-03 2010-09-07 Nektar Therapeutics Method of preparing maleimide functionalized polymers
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
WO2008051178A2 (fr) 2006-04-12 2008-05-02 Savient Pharmaceuticals, Inc. Purification de protéines au moyen d'un tensioactif cationique
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
DK3321359T3 (da) 2005-04-11 2021-03-08 Horizon Pharma Rheumatology Llc Variante former af uratoxidase og anvendelse deraf
CN102807973A (zh) 2005-04-11 2012-12-05 萨文特医药公司 尿酸氧化酶的变体形式及其用途
US8329866B2 (en) 2005-10-03 2012-12-11 Bolder Biotechnology, Inc. Long acting VEGF inhibitors and methods of use
RU2535038C2 (ru) 2009-06-25 2014-12-10 Криэлта Фармасьютикалз ЭлЭлСи Способы и наборы для прогнозирования риска инфузионных реакций и опосредованной антителами потери ответа при терапии пэгилированной уриказой с помощью мониторинга содержания мочевой кислоты в сыворотке крови
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
EP3538135A4 (fr) 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC Polythérapies de molécules de prednisone et d'uricase et leurs utilisations
CN114920819A (zh) * 2022-06-16 2022-08-19 修正生物医药（杭州）研究院有限公司 重组人生长激素突变体、其聚乙二醇衍生物、聚乙二醇衍生物的制备方法及其药物用途
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers
CN117567597B (zh) * 2024-01-17 2024-03-22 成都艾科斯伦医疗科技有限公司 一种抗凝血酶Ⅲ及抗Xa活性检测试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283932A2 (fr) * 1987-03-20 1988-09-28 Hoechst Aktiengesellschaft Serpin hybride et l'ADN l'encodant
WO1991019787A1 (fr) * 1990-06-21 1991-12-26 Invitron Corporation Variantes de la protease nexine-i

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283932A2 (fr) * 1987-03-20 1988-09-28 Hoechst Aktiengesellschaft Serpin hybride et l'ADN l'encodant
WO1991019787A1 (fr) * 1990-06-21 1991-12-26 Invitron Corporation Variantes de la protease nexine-i

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S. JALLAT ET AL: "Altered specificities of genetically engineered alpha-1 antitrypsin variants", PROTEIN ENGINEERING, vol. 1, no. 1, 1986, pages 29 - 35, XP002038981 *
See also references of WO9511987A1 *

Also Published As

Publication number Publication date
AU685187B2 (en) 1998-01-15
AU8076994A (en) 1995-05-22
WO1995011987A1 (fr) 1995-05-04
EP0730660A1 (fr) 1996-09-11
JPH09504174A (ja) 1997-04-28

Similar Documents

Publication Publication Date Title
EP0754227A4 (fr) Proteines chimeres inhibitrices de complement
ZA948551B (en) Chimeric proteins comprising borrelia polypeptides; uses therefor
PL309778A1 (en) Novel peptides
EP0535092A4 (en) Protease nexin-i variants
GB9315303D0 (en) Polypeptide
GB9314802D0 (en) Modified proteins
IL108353A0 (en) Novel peptides
PL302321A1 (en) Antimicrobial proteins
GB9324013D0 (en) Polypeptides
GB9321469D0 (en) Insecticidal proteins
GB9301553D0 (en) Protein synthesis
GB9324691D0 (en) Peptide compounds
GB9126531D0 (en) Novel protease
GB9324819D0 (en) Proteins
IL100926A0 (en) Chimeric proteins
GB9309599D0 (en) Protein libary
GB9315249D0 (en) Antigen-binding proteins
GB9313061D0 (en) Prism assembly
ZA94319B (en) Novel peptides
GB9324818D0 (en) Peptide
GB9311328D0 (en) Protein engineering
GB9313961D0 (en) Chimaeric proteins
GB9409335D0 (en) Peptides
ZA94211B (en) Peptides
ZA934094B (en) BPI-immunoglobulin fusion proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960509

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

RHK1 Main classification (correction)

Ipc: C12N 15/15

A4 Supplementary search report drawn up and despatched

Effective date: 19980112

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE FR GB IT LI NL

17Q First examination report despatched

Effective date: 20000906

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020621